Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women

NCT ID: NCT03223987

Last Updated: 2024-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-11

Study Completion Date

2019-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Before and after study in obese women 25-35 years old, BMI 30-35, taking Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement for three weeks. At the beginning and after three weeks of the study a stool sample is provided. These samples are analysed with 16S rRNA analysis down to species level.The results are interpreted with the PICRUSt classification and Alpha Diversity Analysis and compared to internationally accepted data bases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intervention: Variation of the gut microbiome via intake of an herbal yeast preparation.

Participants: healthy obese women between 25 and 35 years. Intervention to be studied: Intake of Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement over 3 weeks, stool analysis.

Sequence and duration of all study periods: 7 weeks per proband.

Week -4 - -2: Pre-Phase Hand out study information First check of inclusion/exclusion criteria

Week -2: Initiation-Phase Signed "Informed Consent" Second check of inclusion/exclusion criteria Complete assessment Part I, II (see 8.2) Start assessment Part IV (see 8.2)

Week 0: Intervention-Phase Implementation of food supplement Complete assessment Part III (see 8.2) Third check of inclusion/exclusion criteria

Week 3: Evaluation-Phase Complete assessment Part II, III and IV Fourth check of inclusion/exclusion criteria Compliance control

5.2 Methods of minimising bias (ICH/E6 6.4.3; AGEK 4.3; SPIRIT #16, 17) ICH: A description of the measures taken to minimize/avoid bias, including: Randomization, Blinding.

Homogenous sample selection. 5.2.1 Randomisation Not applicable

5.2.2 Blinding procedures Not applicable

5.2.3 Other methods of minimising bias The investigators are going to do a semi-quantitative screening to determine a participant's nutritional habits.

Questions about their nutritional habits asked in the screening (via questionnaire);

1. Does the participant have a particular or alternative lifestyle (e.g. vegan, vegetarian, only eating raw fruits and vegetables, etc.)?

\- if yes → excluded
2. Does the participant control your nutrition in any form (food diary, app, counting calories, etc.)?

\- if yes → excluded
3. Does the participant consciously eat food to strengthen your immune system or do you take additional supplements to influence your intestinal bacteria (e.g. pro- and/or prebiotic food like Actimel, Activia, etc.)?

\- if daily or weekly → excluded
4. Does the participant exercise regularly? If yes, how often? - if 3h/week or more → excluded
5. On how many days per week does the participant eat meat or meat products?

\- if less then twice and more than five times peer week → excluded
6. On how many days per week does the participant eat fish?

\- if less or more than twice per week / 5 times per month → excluded
7. On how many days per week does the participant eat salad, vegetables or vegetable juice (not counting potatoes)?

\- if less than 5 days per week → excluded
8. On how many days per week does the participant eat fruits or drink fruit juices approximately?

\- if less than 5 days per week → excluded
9. On how many days per week does the participant drink or eat milk or milk products approximately? - if less than 4 days per week → excluded

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Before-after intervention, open label study
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

First letter of prename, second and third letter of name.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

The study is one armed

Group Type EXPERIMENTAL

Strath® Kräuterhefe Original (liquid)

Intervention Type DIETARY_SUPPLEMENT

The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.

Stool analysis at 2nd visit and last visit. Before-after study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Strath® Kräuterhefe Original (liquid)

The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.

Stool analysis at 2nd visit and last visit. Before-after study.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women, 25 to 35 years, BMI 30-35
* German speaking
* Smartphone owner

Exclusion Criteria

* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
* Women who are pregnant or breast feeding,
* Intention to become pregnant during the course of the study,
* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
* Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.),
* Known or suspected non-compliance, drug or alcohol abuse,
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
* Participation in another study with investigational drug within the 30 days preceding and during the present study,
* Enrolment of the investigator, his/her family members, employees and other dependent persons
* any kind of nutritional intervention due to a disease in the past 6 months
* any mean of weight reduction in the past 6 months
* Severe health problems in the last 6 months
* Chronic digestive system problems
* Medication against constipation and diarrhea
* Mental problems
* Major surgery
* Allergies or Atopy
* Drug intolerance
* Antibiotics within 12 months before study
Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH

INDUSTRY

Sponsor Role collaborator

Bio-Strath AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter Joller, PhD

Peter Joller, PhD Clinical Immunology FAMH

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter W. Joller, PhD

Role: STUDY_DIRECTOR

Dr.Joller BioMedical Consulting

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Obesity and Metabolism Adimed - Zentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbH Lagerhausstrasse 9

Winterthur, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BS2016.1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.